AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare
LEXINGTON, Mass. -- February 7, 2013
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden,
AMAG’s chief executive officer, will participate in the Leerink Swann Global
Healthcare Conference on Wednesday, February 13, 2013 at 2:00 pm Eastern Time.
The presentation will include a company overview and business update, followed
by a question and answer session with investors.
A live webcast of the presentation will be accessible through the Investors
section of the company’s website at www.amagpharma.com. Following the
conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc.
website until March 13, 2013.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® (ferumoxytol) Injection for Intravenous
(IV) use in the United States. Along with driving organic growth of its lead
product, AMAG intends to expand its portfolio with additional commercial-stage
specialty pharmaceuticals. The company is seeking complementary products that
leverage the company’s commercial footprint and focus on hematology and
oncology centers and hospital infusion centers. For additional company
information, please visit www.amagpharma.com.
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303
Press spacebar to pause and continue. Press esc to stop.